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Bioresponsive probes for molecular imaging:
concepts and in vivo applications
Sander M. J. van Duijnhovena,b, Marc S. Robillardb, Sander Langereisb and
Holger Grülla,b*
Molecular imaging is a powerful tool to visualize and characterize biological processes at the cellular and molecular
level in vivo. In most molecular imaging approaches, probes are used to bind to disease-speciﬁc biomarkers highlight-
ing disease target sites. In recent years, a new subset of molecular imaging probes, known as bioresponsive molecular
probes, has been developed. These probes generally beneﬁt from signal enhancement at the site of interaction with
its target. There are mainly two classes of bioresponsive imaging probes. The ﬁrst class consists of probes that show
direct activation of the imaging label (from “off” to “on” state) and have been applied in optical imaging and mag-
netic resonance imaging (MRI). The other class consists of probes that show speciﬁc retention of the imaging label
at the site of target interaction and these probes have found application in all different imaging modalities, including
photoacoustic imaging and nuclear imaging. In this review, we present a comprehensive overview of bioresponsive
imaging probes in order to discuss the various molecular imaging strategies. The focus of the present article is the
rationale behind the design of bioresponsive molecular imaging probes and their potential in vivo application for
the detection of endogenous molecular targets in pathologies such as cancer and cardiovascular disease. Copyright
© 2015 John Wiley & Sons, Ltd.
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1. INTRODUCTION
Molecular imaging involves the noninvasive visualization and
quantitative detection of biomolecules in vivo by means of
target-speciﬁc probes (1–5). Valuable applications of molecular
imaging are accurate disease detection, phenotyping, and stag-
ing by gathering information on molecular pathways underlying
biological and cellular processes in the diseased tissue (1–6).
Hence, molecular imaging is likely to play a pivotal role in the
stratiﬁcation of patients for personalized treatment. Furthermore,
molecular imaging is clinically relevant in the discovery and
development of drugs and for the real-time assessment of the
efﬁcacy of drug therapy (7,8). Further, it can contribute to
improved interventions by image-guided drug delivery and
image-guided surgery (9–12). Finally, molecular imaging has an
impact in the development of regenerative medicine and stem-
cell therapies (6). In most molecular imaging approaches,
target-speciﬁc molecular probes are engineered to enhance
image contrast at the target site. These conventional targeting
molecular imaging probes consist of a ligand that binds to an
endogenous molecular target and an imaging label for readout.
Typically, the molecular imaging probes are designed so that
they can be injected intravenously for targeting biomolecules
accessible via the blood circulation. For example, the active site
of enzymes has been targeted with conventional probes, provid-
ing a readout for enzyme abundance (13). However, these probes
lack the possibility of detecting enzymatic activity in vivo as they
are typically limited to a 1:1 probe/target binding fashion. In that
respect, a new subset of protease activatable molecular imaging
probes has generated considerable attention. These probes have
been directed to the active site of the enzymes resulting in the
cleavage and activation of the imaging probe (14). Importantly,
this will lead to signal ampliﬁcation since the molecular target
can continuously activate the imaging probe and, moreover, it
offers a readout of enzyme activity instead of enzyme abun-
dance. Although protease activatable probes have been mainly
restricted to ﬂuorescence optical imaging, recent progress has
led to the development of protease activatable probes for photo-
acoustic imaging, magnetic resonance imaging (MRI), and the
nuclear imaging modalities single photon emission computed
tomography (SPECT) and positron emission tomography (PET)
(14–18). Furthermore, activatable molecular imaging probes have
also successfully detected other endogenous molecular targets,
such as reactive oxygen species (ROS) and metal ions. The pur-
pose of this review is to present a general overview of the ratio-
nale behind the design of the multiple types of so-called
bioresponsive molecular imaging probes for the detection of a
wide range of endogenous molecular target. We will guide the
reader through the emerging ﬁeld of bioresponsive molecular
imaging by discussing the various imaging probe strategies and
their potential in vivo application per imaging modality. For opti-
cal imaging and MRI, bioresponsive probes have been reported
that show signal ampliﬁcation by direct activation of the imaging
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label (i.e. probes that go from an “off” to an “on” state) or by
speciﬁc retention of the imaging probe at the site of interaction
through a speciﬁc biological or chemical mechanism. Bio-
responsive probes for photoacoustic imaging and SPECT/PET
have been typically designed to show local retention and accu-
mulation at the site of interaction.
2. BIORESPONSIVE OPTICAL PROBES: ACTI-
VATION OF THE OPTICAL IMAGING LABEL
2.1. Protease sensitive bioresponsive optical probes
Proteases play crucial roles in physiology and pathology and
have been identiﬁed as attractive targets for molecular imaging
of a variety of diseases, including cancer, atherosclerosis,
myocardial infarction, and neurological diseases (14–19). Multi-
ple types of protease bioresponsive optical probes have been
developed in the past decades that are speciﬁcally directed at
the activity of the enzyme instead of enzyme abundance. These
probes include ﬂuorescent autoquenched probes, self-quenched
or homo-ﬂuorescence resonance energy transfer (homo-FRET)
probes, dual-labeled FRET probes, ﬂuorescent quenched
activity-based probes, and luminescent probes (14–19).
2.1.1. Fluorescent autoquenched probes
An autoquenched probe typically consists of a peptide substrate
linked via an amide to ﬂuorescein/rhodamin spirolactam or
spirolactone derivative, which is essentially optically silent (20).
The probe regains its ﬂuorescence upon conversion of the amide
moiety into an amine and subsequent ring-opening of the corre-
sponding spirolactam/lactone (11,21–24) (Fig. 1). For example, a
caspase-3 and 7 autoquenched probe was designed by conju-
gating the peptide substrate DEVD to a rhodamine spirolactone
derivative. Release of DEVD peptide by intracellular caspase-3 or
7 resulted in ring-opening of the spirolactone, followed by a
strong enhancement of ﬂuorescence (25) (Scheme 1). A γ-
glutamyltranspeptidase autoquenched probe was successfully
used for the endoscopic detection of γ-glutamyltranspeptidase
in vivo in a mouse model of colon cancer (11,26). Recently, a
novel self-immolative autoquenched probe has been described.
Here, a naphthalimide dye was conjugated via an electron-
withdrawing self-immolative linker to a trigger group yielding
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an autoquenched probe. Elimination of the self-immolative
linker by enzymatic removal of the trigger yielded a highly ﬂuo-
rescent dye (27).
So far, these autoquenched probes use ﬂuorophores that emit
light in the visible region. Compared to visible light, near-infrared
(NIR) radiation penetrates tissues more efﬁciently, up to several
centimeters, and shows decreased absorption by natural pro-
teins like hemoglobin (15,28,29). Therefore, the development of
autoquenched probes based on NIR ﬂuorophores would be an
interesting strategy to broaden the applications of these
autoquenched probes in vivo.
2.1.2. Fluorescent self-quenched probes
Self-quenched probes or homo-FRET probes are typically macro-
molecular imaging probes that make use of multiple NIR
ﬂuorophores that are in close proximity to each other. When ex-
cited, the ﬂuorophores absorb energy from each other resulting
in self-quenching. The efﬁciency of energy transfer between the






where r is the distance between the ﬂuorophores and R0 is the
Förster distance (30). The Förster distance is the distance at
which the energy transfer efﬁciency is 50% and is typically in
the range of 2–6 nm. Proteolytic activation of these probes
liberates the ﬂuorophores, resulting in the loss of homo-FRET,
activating ﬂuorescence.
Weissleder and coworkers functionalized a poly-L-lysine back-
bone with methoxy-terminated poly(ethylene glycol) and multi-
ple self-quenched NIR Cy5.5 ﬂuorophores. Degradation of the
poly-L-lysine backbone by lysosomal cysteine/serine proteases
resulted in liberation and activation of the ﬂuorophores (31–35).
The range of applications of these macromolecular probes
(~450 kDa), was extended by inclusion of various peptide sub-
strates between the ﬂuorophores and the backbone (Fig. 2).
Following this approach, activatable probes were developed for
a variety of enzyme targets like caspase-1, cathepsins D, E and
K, HIV-1 protease, urokinase, and matrix metalloproteinases
(MMPs) subtype 2 and 9 (36–47). For example, MMP-2 selectivity
was achieved by inserting the MMP-2 sensitive peptide sequence
GPLG-VRGK between the backbone and the ﬂuorophore (44). This
probe showed a threefold enhancement in NIR ﬂuorescence
signal in tumor xenografts overexpressing MMP-2, compared to
tumor xenografts that were treated with an MMP inhibitor (Fig. 2).
These self-quenched macromolecular imaging probes have been
applied for in vivo protease detection in cancer, atherosclerosis,
arthritis, and heart failure in rodent models (31–52). Two of
these macromolecular probes, one sensitive towards MMPs
(MMPSenseTM) and the other towards cathepsins (ProSenseTM),
are commercially available. Recently, a series of self-quenched
probes that comprise a novel architecture termed FASTTM
(ﬂuorescent activatable sensor technology) have become com-
mercially available. In these probes, an enzyme-sensitive peptide
sequence containing NIR ﬂuorochromes at both the C and N
terminus is linked to a polymer carrier at a ratio of one substrate
per polymer molecule (53). The NIR ﬂuorophores show ~95% self-
quenching while the substrate is intact, but become highly
ﬂuorescent upon enzymatic cleavage of the substrate. These
FASTTM self-quenched probes (~43 kDa) are signiﬁcantly smaller
in size compared to the macromolecular poly-L-lysine-based
probes and therefore display an improved pharmacokinetic pro-
ﬁle that enables in vivo molecular imaging at earlier time-points.
These probes have successfully been used for the detection
in vivo of the proteolytic activity of renin, MMPs, cathepsin B,
and neutrophil elastase (52–59).
In recent years, several other activatable self-quenched
ﬂuorescent imaging probes have been developed for protease
sensing. An MMP-9 sensitive liposomal system was developed
that showed in vitro protease-triggered release and activation
Scheme 1. A caspase-3/7 sensitive autoquenched probe. The rhodamine ﬂuorophore is activated upon release of the DEVD peptide substrate by cas-
pase-3/7 (25).
Figure 1. Autoquenched probe. Attachment of a protease substrate to a
ﬂuorophore is designed to result in a nonﬂuorescent structure. Proteo-
lytic removal of the substrate results in the restoration of ﬂuorescence.
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of encapsulated ﬂuorophores in the presence of MMP-9 (60,61).
Here, MMP-9 cleavable lipopeptides were incorporated into the
liposome bilayer. Degradation of the lipopeptide resulted in
destabilization of the bilayer and subsequent leakage and activa-
tion of the ﬂuorescent dyes that were present in the lumen of
the liposomes (Fig. 3).
Another approach of activatable self-quenched probes
focussed on the protease triggered release and activation of
ﬂuorophores from a nanoﬁber precursor for the detection of
urokinase activity (62). The probe comprised a self-assembling
peptide sequence to which a ﬂuorophore was coupled via a
urokinase-sensitive peptide moiety. Spontaneous self-assembly
of the peptide probe resulted in an optically quenched nanoﬁ-
ber, in which the ﬂuorophore was released and activated upon
urokinase digestion in vitro. In a similar approach, a NIR triple
helical peptide-based optical probe was developed. Each
peptide strand was ﬂanked by two NIR ﬂuorescent dyes. In the
triple-helical structure, the ﬂuorescence was reduced due to
quenching. In vivo studies in tumor-bearing mice showed
MMP-mediated degradation of the triple-helical peptide in
tumors, resulting in the local release of ﬂuorophore labeled
peptides and ampliﬁcation of the ﬂuorescent signal (63).
Finally, self-quenched ﬂuorophore-encapsulated nanogels
have been developed that showed release and activation of the
ﬂuorophore upon nanogel degradation by hyaluronidase (64).
2.1.3. Fluorescent dual-labeled FRET probes
The common feature of protease-sensitive dual-labeled FRET-
based molecular imaging probes is the loss of FRET between a
donor ﬂuorophore and a distinct acceptor ﬂuorophore or nonﬂu-
orescent quencher upon enzymatic degradation of a substrate
initially holding the ﬂuorophores together. For the former class,
the distance between the two distinct ﬂuorophores, typically
smaller than Förster radius (eqn 1), results in efﬁcient FRET from
the donor ﬂuorophore to an acceptor ﬂuorophore predomi-
nantly yielding light emission of the acceptor ﬂuorophore.
Proteolysis of the peptide substrate results in separation of the
ﬂuorophores and loss of energy transfer (Fig. 4A). These dual-
wavelength probes can be used for ratiometric imaging, which
provides accurate quantiﬁcation of probe activation. For the
second class, efﬁcient energy transfer will take place between
the donor ﬂuorophore and a nonﬂuorescenct quencher,
resulting in a low ﬂuorescent signal from the donor ﬂuorophore.
Degradation of the substrate results in the dissociation of the
ﬂuorophore–quencher pair and leads to a signiﬁcant enhance-
ment in ﬂuorescence (Fig. 4B). A wide variety of single-
wavelength and ratiometric FRET probes has been described in
literature (59,65–95).
Genetically encoded ﬂuorescent sensors consisting of two dis-
tinct ﬂuorescent proteins are generally aimed at the colorimetric
detection of intracellular proteases such as caspases or kinases
(65,66). These probes typically consist of a protease cleavable
substrate (65) or a conformationally responsive domain (66)
sandwiched between two mutants of the green ﬂuorescent
protein (GFP) capable of FRET. Degradation of the cleavable sub-
strate or a protease-induced conformational change of the linker
domain is associated with a change in distance between the two
ﬂuorescent proteins and thus a change in FRET. For example, a
genetically encoded caspase-sensitive FRET probe consisted of
a cyan ﬂuorescent protein (CFP) and a yellow ﬂuorescent protein
(YFP) joined by a peptide domain sensitive for caspase-1 or
Figure 2. (A) Schematic representation of a self-quenched polymer-
based probe. Multiple ﬂuorophores coupled to a backbone lead to self-
quenching of the ﬂuorophores. Upon proteolytic degradation of the
probe, the ﬂuorescence is restored. (B) The table shows applied peptide
substrates resulting in the development of a variety of enzyme-speciﬁc
self-quenched probes (36–47). (C) In vivo NIR ﬂuorescence image of
MMP-2 positive HT-1080 tumor-bearing animals using a MMP-2 sensitive
self-quenched probe. A threefold higher ﬂuorescent signal was observed
in tumors of untreated tumor-bearing mice (left) compared to tumor-
bearing mice that were treated with the MMP inhibitor prinomastat
(right). Figure C is reprinted with permission from (44).
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caspase-3 (65). Proteolysis of the peptide domains signiﬁcantly
enhanced the distance between CFP and YFP, and resulted in a
decrease in FRET. Recently, novel genetically encoded biosensors
have been reported that visualize MMPs at the extracellular
surface of the cell membrane (67–69). Although recent progress
led to the development of NIR ﬂuorescent proteins enabling
deep tissue imaging (96,97), the need for gene transfection is a
strong limitation to clinical application in humans. However, it
is a powerful research tool in the preclinical setting.
In other strategies, organic NIR ﬂuorophores have been suc-
cessfully employed in low molecular weight activatable FRET-
based probes. For example, an MMP-7 peptide substrate was
ﬂanked with the organic Cy5.5 ﬂuorophore and the organic NIR
quencher NIRQ820 (70). A sevenfold increase in ﬂuorescence
was observed upon incubation with MMP-7. Recent research
has resulted in the development of activatable organic FRET
probes speciﬁcally targeting extracellular proteases (59,71–83).
One of these probes, a membrane-type MMP sensitive probe,
consisting of the MMP-14 peptide substrate GRIGF-LRTAKGG
and a Cy5.5/BHQ-3 NIR dye-quencher pair, was successfully used
to detect MMP-14 activity in tumor-bearing mice (Fig. 5) (79).
Moreover, intracellular enzymes have been effectively targeted
with organic activatable FRET imaging probes (84–89). For exam-
ple, cell-permeable caspase activatable probes were developed
for the noninvasive detection of apoptosis in vivo (84–88). These
probes consisted of a Tat-peptide-based permeation sequence
and a caspase recognition sequence (DEVD) ﬂanked by a NIR
dye-quencher pair.
A special subclass of FRET probes are the ﬂuorescent
quenched activity-based probes (ABPs) (90). Fluorescent
quenched ABPs undergo an enzyme-catalyzed chemical reaction
resulting in a covalent bond between the catalytic site and the
probe. This reaction is furthermore characterized by a nucleo-
philic displacement of the quencher group, resulting in activa-
tion of the ﬂuorescent tag. In contrast to the classic FRET
probes, the molecular target cannot continuously activate ABP
probes due to the covalent bond formation. Nevertheless, cyste-
ine cathepsin activity has successfully been detected in vivo with
ﬂuorescent quenched ABPs (91,92).
Apart from organic ﬂuorophores, inorganic particles like quan-
tum dots and gold nanoparticles have recently been exploited as
Figure 3. Depiction of a self-quenched probe based on protease-de-
gradable liposomes. Multiple ﬂuorophores encapsulated in the aqueous
lumen of a liposome lead to self-quenching of the ﬂuorophores. Upon
proteolytic degradation, the liposomes fall apart and the ﬂuorophore is
released, resulting in restoration of ﬂuorescence.
Figure 4. Dual-labeled FRET-based probes, based on protease sub-
strates labeled with (A) two distinct ﬂuorophores or (B) a ﬂuorophore-
quencher pair.
S. M. J. VAN DUIJNHOVEN ET AL.
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donor and acceptor pairs for energy-transfer-based imaging
probes (93,94). Gold nanoparticles demonstrated a 71% reduc-
tion of quantum dot photoluminescence, as was shown for an
MMP activatable quantum-dot-based luminescent probe (95).
Quantum dots have advantages over organic ﬂuorophores, such
as strong ﬂuorescence, higher photostability against bleaching
and changes in physical environment, such as temperature and
pH, and a narrow emission bandwidth (98). Nevertheless quan-
tum dots may have limitations for in vivo use due to potential
cellular toxicity associated with Cd2+ or Se2 ion release from
the quantum dot core (99). Recent studies, however, indicated
that potential toxicity is of minor importance for relatively small
nanoparticles, such as quantum dots and chemical dots, which
are efﬁciently cleared by the kidney’s thus avoiding extensive
liver and spleen uptake (100,101). Speciﬁcally, quantum dots
with a hydrodynamic diameter smaller than 5.5 nm showed
efﬁcient renal excretion (101).
Recently, the principles of FRET imaging and photodynamic
therapy (PDT) have been combined into the development of en-
zyme activatable photodynamic molecular beacons (102–106). In
photodynamic therapy (PDT), the cytotoxic agent 1O2 is gener-
ated by light activation of a photosensitizer in the presence of
oxygen (107). Furthermore, NIR light emission from the photo-
sensitizer is typically observed. Activatable photodynamic
molecular beacons have been developed for MMP-7, caspase 3,
and ﬁbroblast activation protein, by ﬂanking enzyme-speciﬁc
substrates with a photosensitizer and a ﬂuorescence/1O2
quencher (103–106). NIR ﬂuorescence imaging of a MMP-7 sensi-
tive photodynamic molecular beacon showed tumor-speciﬁc
activation in vivo, suggesting tumor-speciﬁc delivery of the
photosensitizer, which potentially will contribute to improved
tumor-speciﬁc photodynamic therapy (103).
2.1.4. Bioresponsive luminescent probes
Bioluminescence is typically observed upon enzymatic oxidation
of speciﬁc substrates by luciferases (108). In bioluminescence im-
aging, the light production does not rely on external excitation,
and therefore background signals due to tissue autoﬂuorescence
are not present. Luminescent activatable probes, known as
caged luciferase substrates, combine the production of biolumi-
nescence by luciferases with the enzymatic activity of other pro-
teases. In these probes, D-luciferin, the substrate for luciferase, is
typically protected by a speciﬁc enzymatic trigger (Scheme 2).
The presence of the enzymatic trigger prevents the enzymatic
oxidation of the probe by luciferase. However, upon enzymatic
digestion of the trigger, D-luciferin is released and will produce
a bioluminescent signal once consumed by luciferase. In
vivo, luminescent activatable probes have successfully been
employed to visualize a variety of enzymes, including
β-galactosidase (reporter enzyme), β-lactamase, caspase, and
furin (109–112). A recent study demonstrated that D-cysteine
and 2-cyanobenzothiazoles (CBT) selectively react with each
other in vivo to yield D-luciferin (113). A bioresponsive lumines-
cent probe was developed by conjugating D-cysteine to a caspase
3/7 substrate. In vivo release of D-luciferin from the caspase 3/7
sensitive probe in luciferase-expressing tumor-bearing mice
allowed the reaction with administered 6-amino-CBT to form
Figure 5. (A) Molecular structure of the MMP-14 substrate GRIGF-LRTAKGG ﬂanked by the NIR dye Cy5.5 and the NIR quencher BHQ-3. (B) In vivo NIR
ﬂuorescence image of MMP-14-positive MDA-MB-435 tumor-bearing animals using the MMP-14 FRET probe. A three- to fourfold higher ﬂuorescent sig-
nal was observed in tumors of untreated mice (top row) compared to mice that were treated with the MMP inhibitor prinomastat (bottom row). Figure
B is reprinted with permission from Zhu et al. (79). Copyright 2011 American Chemical Society.
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6-amino-D-luciferin. Subsequently reaction of 6-amino-D-luciferin
with luciferase yielded a bioluminescent signal (113). Similar to
ﬂuorescent genetically encoded FRET probes, activatable lumi-
nescent probes are valuable for preclinical studies, but clinical
translation is restricted due to the need for gene transfection of
the luciferase gene. Interestingly, a recent study has demon-
strated that it may become possible to enlist endogenous
enzymes from nonluminescent organisms such as luciferases,
circumventing the need for genetic manipulation (114).
2.2. pH-sensitive optical probes
The important role of intracellular pH in cell, enzyme, and tissue
activity as well as the recognition that the tumor’s extracellular
microenvironment is relatively acidic compared to normal tissue
has stimulated the development of pH-sensitive ﬂuorescent
imaging probes (115–129). On average, the pH in the tumor mi-
croenvironment is between 6 and 7 (130). In the early days, pH-
dependent probes were aimed at the enhancement of
ﬂuorescence of the GFP upon a decrease in pH (110). Other
strategies focussing on pH-dependent activation of the ﬂuores-
cent imaging label used pH-sensitive nanoparticles, for example,
liposomes or polypeptides that showed release and activation of
ﬂuorescence of self-quenched ﬂuorophores at low pH (119–121).
More recently, low molecular weight pH-sensitive autoquenched
ﬂuorescent probes have been developed (Fig. 6). Most of these
probes are speciﬁcally targeted to tumors and become ﬂuores-
cent once accumulated in acidic lysosomes, typically having a
pH varying from 4 to 6 (122–128). For example, a near-infrared
pH-activatable ﬂuorophore conjugated to a RGD-peptide was
successfully used for the targeting of αvβ3 integrin-expressing tu-
mors (124). Subsequent αvβ3 integrin-mediated internalization of
the probe into acidic lysosomes resulted in an enhancement of
ﬂuorescence. Recently, a self-assembled self-quenched imaging
probe has been developed that showed efﬁcient disassembly
and activation of ﬂuorescence at pH < 7.0 (129).
2.3. Optical probes activated by reactive oxygen/nitrogen
species
Reactive oxygen species and reactive nitrogen species (RNS) play a
crucial role in maintaining normal physiology. However, excessive
production of ROS/RNS has been associated with a variety of patho-
logical diseases, such as cancer and cardiovascular disease (131,132).
Activatable ﬂuorescent imaging probes for ROS/RNS detection are
mainly based on autoquenched probes in which a ﬂuorophore is
coupled to a ROS/RNS trigger, resulting in a nonﬂuorescent molecule
(20,133). Reaction of these probes with ROS/RNS results in the activa-
tion of the ﬂuorescent moiety (Scheme 3). This approach has been
extensively exploited, resulting in activatable ﬂuorescent probes for
a range of ROS/RNS, including hydrogen peroxide (H2O2) (134–
141), peroxynitrite (ONOO) (142–146), superoxide (O2
) (147–149),
nitric oxide (NO) (150–152), hypochlorous acid (HOCl) (142–
144,153–155), and hydroxyl radical (·OH) (144,156). Other imaging ap-
proaches have focussed on the colorimetric detection of ROS/RNS
(157–160) or used genetically encoded biosensors (161–163).
ROS/RNS imaging methods have been applied in cell-culture
experiments in vitro, but strategies to visualize ROS/RNS in vivo
have been limited (142,164–167). The ﬁrst in vivo study
employed nanoparticles formulated from peroxalate esters and
ﬂuorescent dyes (164). Reaction of the peroxalate esters with
H2O2 resulted in high-energy dioxetanedione intermediates that
subsequently facilitated excitation of the encapsulated dye. This
probe was used to detect H2O2 in the peritoneal cavity of mice
during a lipopolysaccharide-induced inﬂammatory response.
H2O2 production was also visualized in tumor-bearing mice
using a peroxy-caged luciferin-1 bioluminescent probe (165).
Selective reaction of this probe with H2O2 released ﬁreﬂy
Scheme 2. A caspase-3/7 sensitive activatable bioluminescent probe. D-luciferin is released upon cleavage of the DEVD peptide substrate by caspase-
3/7 and is subsequently consumed by luciferase, resulting in a bioluminescent signal (111).
S. M. J. VAN DUIJNHOVEN ET AL.
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luciferin that subsequently was converted to a bioluminescent
active moiety by ﬁreﬂy luciferase. This probe was studied in
luciferase-expressing tumor-bearing mice and showed tumor-
speciﬁc activation. In a follow-up study, a dual-analyte bio-
luminescent strategy was developed for the simultaneous
detection of H2O2 and caspase (166). In this approach, two com-
plementary bioorthogonal caged precursors (6-hydroxy-2-
cyanobenzothiazole (HCBT) and D-cysteine) were unmasked by,
respectively, H2O2 and caspase 8. After their release, the HCBT
and D-cysteine cages react with one another and form luciferin,
producing a bioluminescent signal upon reaction with luciferase.
An in vivo study in a luciferase-expressing mouse model of in-
ﬂammation demonstrated proof-of-concept for this dual-analyte
detection technology (166). Panizzi et al. developed a ROS/RNS
nanoparticle to which quenched oxazine reporters were conju-
gated (142). Release of the oxazine reporters by ROS/RNS inter-
action, in particular ONOO and HOCl, resulted in restoration
of its ﬂuorescence. This nanoparticle was studied in a mouse
model of myocardial infarction and showed enhancement of
oxazine ﬂuorescence in the infarcted areas of the heart. Lastly,
a H2O2 ratiometric FRET probe has recently been developed
employing ﬂuorescein and Cy-5 as a donor/acceptor FRET pair
(167). Reaction of this probe with H2O2 led to a decrease in FRET
and subsequent increase in ﬂuorescein ﬂuorescence, as was
demonstrated in vitro and in vivo in a mouse model of lung
inﬂammation.
2.4. Optical probes activated upon target binding
The ﬁnal class of bioresponsive ﬂuorescent imaging probes
shows a change in FRET between a donor ﬂuorophore and ac-
ceptor ﬂuorophore or quencher upon target binding. For in-
stance, various genetically encoded FRET sensors based on
GFP-mutants undergo a conformational change upon target
binding and allowed the in vitro ratiometric detection of, for ex-
ample ATP, glucose, and metal ions like calcium, zinc, and
cadmium (168–172). Another strategy is focussed on FRET
oligonucleic acid-based aptamer probes in which a ﬂuorescent
label is efﬁciently activated upon a conformational change of
the probe induced by binding to a biomarker (Fig. 7) (173,174).
Alternatively, micellar and liposomal formulations containing
high concentrations of self-quenched ﬂuorescent dyes have been
developed that destabilize and release the ﬂuorescent dyes upon
target binding, cellular internalization, and subsequent
nanocarrier degradation (175,176). Similarly, various FRET probes
have been developed that upon target binding and subsequent
cellular internalization showed activation of the optical imaging
label (177–179).
2.5. Fluorescence lifetime imaging
For most ﬂuorescence techniques, the increased ﬂuorescence in-
tensity upon activation of the optical imaging probe is used as a
Figure 6. (A) Reaction mechanism showing the reversible pH-dependent ﬂuorescence activation of a pH-sensitive optical probe. In the native state,
the probe is essentially nonﬂuorescent due to intramolecular photon-induced electron transfer from the aniline moiety to the ﬂuorophore. Once pro-
tonated, the probe becomes highly ﬂuorescent. (B) pH proﬁles of ﬂuorescence for various pH-sensitive ﬂuorescence probes. The pH ranges from 2 (left)
to 9 (right) in single pH unit increments. Figure B is reprinted (adapted) with permission from (122).
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measure of activation. Next to ﬂuorescence intensity, the ﬂuo-
rescence lifetime (FLT) properties of the ﬂuorophores change
due to activation of the probe (180). The ﬂuorescence lifetime
describes the length of time between the excitation of a
ﬂuorophore and subsequent ﬂuorescent emission and can be in-
ﬂuenced by changes in the environment. For example, energy
transfer between the donor and acceptor ﬂuorophore in FRET-
based imaging probes results in a lower quantum yield as well
as decrease of the ﬂuorescence lifetime of the donor ﬂuorophore
(181). Upon probe activation, the quantum yield and lifetime are
restored, resulting in an increase in ﬂuorescence intensity and
lifetime of the donor ﬂuorophore. Consequently, monitoring
the ﬂuorescence lifetime can be utilized to assess whether
in vivo probe activation has occurred (182).
2.6. Clinical application of optical imaging probes
The previous paragraphs present an overview of bioresponsive
optical imaging probes. A unique feature of optical imaging is
that the imaging probes can be turned on upon activation by a
speciﬁc endogenous molecular target, allowing high target-to-
background ratios compared to conventional targeting probes.
Scheme 3. Reaction mechanism of various ROS/RNS activatable ﬂuorophores. Shown are turn-on ﬂuorescein derivatives for (A) H2O2, (B) ONOO
, (C)
O2
, (D) NO, and (E) HOCl.
Figure 7. Schematic representation of an activatable aptamer probe. In
the absence of a target, the probe is typically in a hairpin conformation,
resulting in quenched ﬂuorescence. Upon target binding, its conforma-
tion is altered, resulting in activation of the ﬂuorophore.
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Unfortunately, the limited depth of light penetration through
human tissue hampers the application of optical imaging probes
for image-based whole-body diagnostics in vivo. However, in
recent years these probes have been demonstrated to have a
high potential in intraoperative imaging approaches of surface-
located tissues, such as those encountered during endoscopic
or optically guided surgical interventions (6,10–12,183–185). A
ﬁrst study in a human showed the efﬁcacy of a folate receptor-
α targeting non-NIR ﬂuorescence imaging probe for image-
guided tumor margin detection during cancer surgery (186). This
study and various other studies provide essential proof-of-
principle that intraoperative optical imaging holds great promise
to become a standard clinical tool in cancer treatment (186–197).
While the pioneering studies in a human employed targeted
optical imaging probes, multiple bioresponsive optical imaging
probes are currently also in the process of obtaining regulatory
approval for clinical proof-of-principle studies (198).
3. BIORESPONSIVE PHOTOACOUSTIC
IMAGING PROBES
It has been shown recently that NIR ﬂuorophores can also be
used for photoacoustic tomography (PAT) (199). This technique,
which is one of fastest growing imaging modalities in recent
years (200), is based on the monitoring of ultrasonic signals
generated in response to light absorption properties of speciﬁc
endogenous molecules, such as hemoglobin or exogenously
administered imaging probes. In more detail, photoabsorbing
molecules absorb light from nonionizing laser pulses, resulting
in subsequent energy dissipation as heat. This process subse-
quently leads to thermal expansion and emission of broadband
acoustic waves. The ultrasonic waves can be detected with
adequate ultrasonic transducers, up to several centimeters in
large animals and humans (15). The signal is subsequently proc-
essed with reconstruction algorithms to recover the initial
absorbed energy distribution. Thus, photoacoustic imaging is a
hybrid technique making use of optical absorption and ultra-
sonic wave propagation. Thereby, photoacoustic imaging com-
bines the advantages of both techniques: the high contrast of
optical imaging and the high resolution of ultrasonic imaging,
which offers great promise for this novel imaging modality in
future clinical applications (15). An optimal photoacoustic imag-
ing probe is characterized by a high extinction coefﬁcient that
furthermore possesses efﬁcient conversion of the electromag-
netic energy into mechanical energy. Despite NIR ﬂuorescent
dyes that do show ﬂuorescence, these chromophores have been
proven to be attractive for photoacoustic imaging because of
their relatively low quantum yield. Therefore, a major part of
the absorbed energy, more than 80%, is transferred to
optoacoustic signals (201). Furthermore, the speciﬁc use of NIR
chromophores as photoacoustic imaging agents in combination
with excitation light of a corresponding wavelength allows back-
ground signal suppression, because of the low absorbance of en-
dogenous photoabsorbers present in normal tissue in the NIR
wavelength window (15). In recent years, several bioresponsive
photoacoustic imaging probes have been developed. Razansky
et al. explored the use of MMPSenseTM 680 for multispectral
photoacoustic imaging (201). They demonstrated that the chro-
mophores in MMPSenseTM 680 show an absorption change upon
enzymatic activation, which could be detected by multispectral
photoacoustic imaging at 635 and 675 nm. This approach
allowed high accurate three-dimensional photoacoustic imaging
of MMP activity in human carotid plaques (201). In other work,
Levi et al. developed an MMP activatable cell-penetrating pep-
tide labeled with two chromophores, BHQ3 and Alexa750, which
show photoacoustic signals upon laser irradiation at 675 and 750
nm respectively (202). It was demonstrated that activation of the
imaging probe in vitro resulted in efﬁcient cellular uptake of the
cell-penetrating peptide domain labeled with BHQ3, while the
counterpart containing Alexa750 diffused away, as was con-
ﬁrmed by photoacoustic signal intensity of both chromophores
(202). This probe was subsequently explored in vivo and multi-
spectral photoacoustic imaging was used to detect tumor-
associated MMP activity in mice (203). In another study,
ratiometric multispectral photoacoustic imaging using an
activatable imaging nanoprobe was successfully demonstrated
for detection of cancer-associated MMP activity in vivo (204).
The nanoprobe consisted of multiple chromophores BHQ-3 that
were conjugated via MMP cleavable linkers to copper sulﬁde
nanoparticles. Both BHQ-3 and the copper sulﬁde nanoparticles,
which exhibit distinctive absorption peaks at 680 nm and 930
nm respectively, generate optoacoustic signals upon laser radia-
tion. Activation of this nanoprobe by tumor-associated MMPs re-
sulted in the release and tumor wash-out of the small molecular
weight BHQ-3 molecules, while the large CuS nanoparticles were
retained for much longer in the tumor. Multispectral photo-
acoustic imaging of the signal ratio 680 nm/930 nm conse-
quently showed a decrease in ratio in tumor tissue in vivo and
demonstrated the use of this probe for proteinase activity
detection in vivo (204). Lastly, novel activatable photoacoustic
probes have been developed for photoacoustic lifetime imaging
(205–207). In one strategy, a protease sensitive imaging probe
has been proposed that contains self-assembled methylene blue
chromophores. Upon enzymatic activation, the chromophore
monomers will be released, which will result in a change in the
excited state lifetime of the chromophore (205). The same
chromophores demonstrated pO2 dependent relaxation (206).
A follow-up study proved that these chromophores could be
used for photoacoustic lifetime imaging of hypoxia in vivo in
tumor-bearing mice (207). In summary, photoacoustic imaging
is one of the youngest members of the molecular imaging com-
munity. It is foreseen as a future noninvasive clinical tool for
accurate detection and characterization of, for example, carotid
plaques in patients (201) and is characterized by an exceptional
improved imaging depth compared to optical imaging. Further-
more, photoacoustic imaging can be easily combined with tradi-
tional ultrasound, which will provide anatomic, functional, and
molecular information with a single image (15).
4. BIORESPONSIVE MRI PROBES:
ACTIVATION OF THE MRI CONTRAST AGENT
In contrast to optical imaging, MRI can be employed for whole-
body diagnostic imaging in humans. MRI presents an attractive
platform for molecular imaging due to the conjunction of high-
resolution anatomical imaging and mapping of the activity of
speciﬁc biomarkers by MRI contrast agents. Unlike optical or
radiolabeled molecular imaging probes, MRI contrast agents,
such as gadolinium chelates, do not directly generate a signal
but are detected through their ability to shorten the water
proton relaxation times, that is, the longitudinal (spin–lattice)
and transverse (spin–spin) relaxation times (T1 and T2,
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respectively) (208). In a T1-weighted MRI image, T1-shortening re-
sults in positive contrast (bright spots), whereas in a T2-weighted
image, T2-shortening generates negative contrast (dark areas).
The longitudinal relaxivity (r1) of a contrast agent is modulated
by several parameters (209,210), including the number of inner
sphere water molecules directly coordinated to paramagnetic
complex (q), τm the exchange rate of the metal-coordinated
water molecule with the bulk water, and τR the rotational corre-
lation time of the contrast agent (Fig. 8). Smart MRI contrast
agents have been developed that show a change in one of these
parameters upon activation due to a biochemical stimulus
leading typically to an increase in r1. Typically, these MRI contrast
agents go from an “off” state, with a minimal effect on T1/T2,
to an “on” state, with a large effect on T1/T2 shortening
(17,210,211). In the next paragraphs, we will present an overview
of MRI imaging probes that generate a change in contrast as a
result of activation of the MRI contrast agent. Interestingly,
during the preparation of this manuscript, an in-depth review
speciﬁcally focussed on responsive MRI probes has been
reported (212).
4.1. Bioresponsive T1-weighted MRI contrast agents
4.1.1. Longitudinal relaxivity enhancement via modulation of
water coordination sites
Several strategies have been explored to enhance the longitudi-
nal relaxivity of paramagnetic gadolinium complexes after its
activation due to an increase in the number of water molecules
directly coordinated to the metal centre (Scheme 4). The ﬁrst
enzymatic activatable agent has been reported by Meade and
coworkers (213,214), in which the water coordination site of
gadolinium complex was blocked with a galactopyranosyl ring
reducing “q” (q << 1). Its enzymatic cleavage by the reporter
enzyme β-galactosidase restores the water coordination site
(q = 1) leading to an efﬁcient T1-shortening. Another class of
gadolinium-based agents can interact with endogenous metal
ions, such as Ca2+ and Zn2+, resulting in an increase in water
coordination sites and thus improved longitudinal relaxivity
(215,216). A third class of activatable MRI contrast agents uses
pH-responsive gadolinium chelates that display relaxation en-
hancement at acidic conditions (217–219). Finally, a recent class
used redox responsive gadolinium chelates, for which q does
increase upon reaction with NADH (220). Despite the develop-
ment of various bioresponsive MR imaging probes of this class
(213–220), exploration in vivo has been limited (221). A cell-
permeable Zn2+ sensing MR imaging probe showed the detec-
tion of elevated Zn2+ levels in the hippocampus in rats (221). Im-
portantly, intracranial injection of the imaging probe was
performed to obtain sufﬁcient imaging probe concentration in
the brain. Typically, the exogenous imaging probe concentration
at the target site should be >1 uM because of the relatively low
sensitivity of MRI, which requires relative high biomarker concen-
trations (212). Furthermore, there is a need for efﬁcient cellular
transport of most of these agents to reach their intracellular tar-
gets. Therefore, to apply these probes in vivomay be challenging,
especially in case of intravenous injection, and may limit clinical
translation.
Reducing the water mobility can modulate changes in the lon-
gitudinal relaxivity of the protons of water molecules. For exam-
ple, pH-sensitive micelles and liposomes have been reported
containing gadolinium-based complexes in its aqueous lumen
(222–224), which have a low effect on the longitudinal relaxivity
of the protons of the bulk water molecules due to the limited
transmembrane water exchange rate. At low pH, the contrast
agents are released and a strong increase in the longitudinal
relaxivity is observed. In another approach, gadolinium chelates
were efﬁciently quenched by encapsulation in the polymer coat-
ing of a superparamagnetic iron oxide particle (225). In acidic
environments the Gd chelates were efﬁciently released with a
subsequent increase in longitudinal relaxation rate.
4.1.2. Relaxivity enhancement via modulation of rotational
correlation time
T1-shortening of the protons of water molecules can be achieved
by slowing down the molecular tumbling rate of the paramag-
netic complex (1/τR) (226). Nivorozhkin and coworkers have
developed a carboxypeptidase B activatable MRI contrast
agent that gained afﬁnity for the high molecular weight
Figure 8. Schematic representation of the most relevant parameters
that inﬂuence the relaxation of a gadolinium-DTPA-based MRI contrast
agent: the rotational correlation time (τR) and the mean residence time
of the water molecules at the inner sphere (τm).
Scheme 4. Gd3+-based MRI contrast agents displaying an increase in
water coordination sites upon activation, and thus enhanced longitudinal
relaxivity. (A) Enzymatic activation of a galactopyranosyl-masked Gd3+-
DOTA by β-galactosidase (214). (B) Activation of an MRI contrast agent
by a conformational change upon Ca2+ target binding Y.
S. M. J. VAN DUIJNHOVEN ET AL.
wileyonlinelibrary.com/journal/cmmi Copyright © 2015 John Wiley & Sons, Ltd. Contrast Media Mol. Imaging 2015, 10 282–308
292
protein albumin upon activation, resulting in a reduced tum-
bling rate and therefore higher relaxivity (227). In similar ap-
proaches, activatable albumin/protein-binding Gd-based MRI
contrast agents have been developed for the detection of re-
porter enzyme β-galactosidase, carbonic anhydrase, and zinc
in vitro (228–231). In another approach, Gd-based MRI contrast
agents showed polymerization upon speciﬁc activation by
myeloperoxidase (MPO), resulting in a slower tumbling rate
and therefore in an enhancement of the longitudinal relaxivity
(232–236) (Fig. 9). In this approach, Gd-labeled phenol deriva-
tives are oxidized by MPO, resulting in tyrosyl radicals, which
will form dityrosine cross-links. Using this approach, MPO
activity was visualized in a mouse model of myocardial
infarction in vivo (233).
4.2. Bioresponsive T2–weighted MRI contrast agents
Superparamagnetic iron oxide (SPIO) nanoparticles are widely
used as T2-weighted MRI contrast agents. Recently, it has been
shown that clusters of SPIOs display faster T2 relaxation proper-
ties of the individual iron oxide cores compared to the non-
clustered iron oxide cores. Furthermore, clustering results in an
increased concentration of the MRI contrast agent and, there-
fore, both processes contribute to an enhanced transverse
relaxivity (237). Activatable SPIOs have been developed that
cluster upon activation by MPO. In this approach, dopamine
was attached to the surface of the SPIOs. In the presence of
MPO and H2O2, this phenol derivative is transformed into a
tyrosyl radical that causes dityrosine cross-links between the
nanoparticles (238). In another strategy, biotin and neutravidin
coated SPIOs were shielded with polyethylene glycol (PEG) that
could be proteolytically removed by MMP-2 to initiate
self-assembly (239,240) (Fig. 10). In a related approach,
Schellenberger et al. designed iron oxide particles sterically
stabilized by PEG that showed signiﬁcant aggregation by inter-
particle electrostatic and magnetic attraction upon MMP-9-
induced dePEGylation (241). Finally, Atanasijevic et al. reported
on SPIOs that were functionalized with calmodulin, a Ca2+ sens-
ing protein, and showed Ca2+-dependent protein–protein inter-
action driving particle clustering (242).
In contrast to the clustering of SPIOs, several iron-oxide-based
imaging probes have been developed that show disassembly
upon probe activation, resulting in a loss of relaxivity enhance-
ment. In these disassembly approaches the individual iron oxide
particles are connected to each other by cleavable linkers. Fol-
lowing this strategy, probes has been developed for the sensing
of caspase-3, MMP-2, and endonucleases in vitro in experimental
settings (243–245). The fact that enzyme activation results in loss
of relaxivity enhancement challenges applications of this
approach for imaging in vivo.
In another strategy (246), iron oxides were encapsulated in a
polymer coating restricting the interaction of the iron oxide core
with surrounding water. In vitro enzymatic degradation of the
dextran coating by dextranase resulted in a strong T2 shortening.
4.3. Bioresponsive paramagnetic CEST MRI agents
Another class of activatable paramagnetic MRI contrast agents
induces MR contrast enhancement utilizing chemical exchange
saturation transfer (CEST) (17,247). Typically, these CEST MRI
contrast agents consist of lanthamide complexes containing ex-
changeable water protons with a large chemical shift compared
to the bulk water protons. Upon irradiation of these exchange-
able water protons using a selective radiofrequency pulse, the in-
tensity of the bulk water signal is reduced via chemical exchange
saturation transfer. Bioresponsive paramagnetic CEST agents
have been designed that display a change in the CEST effect
upon interaction with a biochemical stimulus (17,247). For in-
stance, Pagel and coworkers reported on a paramagnetic CEST
agent that showed urokinase plasminogen activator (uPA)
speciﬁc degradation, whereby an amide was cleaved and trans-
formed into an amine, which caused disappearance of CEST
(248) (Fig. 11). In another approach, a redox sensitive CEST agent
was developed that could switch between paramagnetic Co(II)
Figure 9. (A) Chemical structure of a MPO polymerizable Gd3+-DTPA-based MRI contrast agent (232). (B,C) Mechanism of MPO catalyzed polymeriza-
tion resulting in an increased local concentration of the MRI contrast agent Gd3+ and enhanced T1-relaxivity.
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with a high CEST signal to a diamagnetic Co(III) state with a low
CEST signal (249). Oxidation of the CEST agent resulted in Co(III)
and a reduction in CEST signal, as was demonstrated in vitro
(249). Various other bioresponsive CEST agents have been devel-
oped to monitor pH differences, redox status, ROS, metabolites,
enzymes, and minerals (250–262). Most of these probes have
been limited to validation in vitro, while studies in vivo are
needed to reveal potential clinical translation. A particular chal-
lenge may be to obtain sufﬁcient concentration of imaging
probes at the target site, especially in the case of intracellular tar-
gets. Importantly, two recent papers have explored the use of
bioresponsive CEST agents in vivo (248,263). First, an uPA sensi-
tive CEST agent, which showed disappearance of CEST upon ac-
tivation, was used to detect uPA in tumor-bearing mice (248).
The other preclinical study was performed with a hypoxia-
sensitive CEST agent (263). This CEST agent contained two para-
magnetic nitroxide free radical groups that quenched the CEST
signal due to rapid T1 relaxation of water by the nitroxide un-
paired electrons. Upon reduction to bis(hydroxylamine) in hyp-
oxic areas, the T1 relaxation is restored and the CEST signal is
activated. Reduction of this probe in vivo was successfully de-
tected and warrants further research in preclinical models of dis-
ease (263).
A general drawback for all the above activatable MRI contrast
agents is the need for a pre- and post-MRI scan to calculate con-
trast changes by subtraction of the two images, which requires
strict image registration to prevent any artefact. This is especially
challenging if probe activation takes time and one scan session
is not enough. Furthermore, any morphological changes be-
tween scans (e.g. tumor shrinkage due to therapy) strongly
hampers correct image subtraction and ﬁnal interpretation.
4.4. Bioresponsive hyperpolarized MR agents
A ﬁnal class of activatable MR contrast agents are hyperpolarized
probes useful for imaging of metabolic pathways (264). Hyperpo-
larization of the probe results in a signiﬁcant redistribution of the
populations of nuclear spins in a magnetic ﬁeld, leading to a sig-
nal increase by a factor of 10,000 or more. Whereas the concen-
tration of endogenous metabolites is below the detection
threshold of MRI, hyperpolarized metabolic molecules can be
detected and are widely used to study changes in cancer-
associated metabolic pathways (264). Importantly, the relaxation
of the hyperpolarized agents will be determined by the T1 relax-
ation time. For that reason, typical long-life T1 atoms such as
13C
(>20 s half-life) are best-suited for this technology. Multipe 13C
metabolic agents have been developed and investigated
in vitro and/or in vivo, such as 13C-hyperpolarized lactate, pyru-
vate, fructose, and glutamine (264–266). For example,
hyperpolarized [5-13C]glutamine was used to study glutaminase
activity in vivo in liver cancer metabolism in rats (265). Very re-
cently, a ﬁrst study in a human was successfully performed with
hyperpolarized [1-13C]pyruvate to characterize tumor metabo-
lism in prostate cancer, indicating that clinical translation of this
technology is feasible (266).
5. BIORESPONSIVE PROBES FACILITATING
SITE-SPECIFIC RETENTION OF THE IMAGING
LABEL
Activation of autoquenched, self-quenched, and FRET optical
probes results in the transition of a ﬂuorophore from an “off”
state to an “on” state or FRET between a donor and acceptor
ﬂuorophore. For the imaging probes that are activated by extra-
cellular proteases, for example MMPs, the ﬂuorophores may dif-
fuse away from the cleavage site, resulting in lower signal-to-
background ratios (267). Similarly, activatable MRI contrast
agents might show wash-out after activation, except for the
activatable SPIOs. In order to avoid wash-out, a special class of
activatable probes has been developed in which the ﬂuorescent
or MRI imaging label is not activated, but probe activation leads
to retention of the imaging probe at the activation site, thereby
accumulating the imaging label in the target tissue and thus in-
creasing signal. Importantly, these types of imaging probes are
not limited to one speciﬁc imaging modality. Therefore, this ap-
proach led to the successful development of bioresponsive nu-
clear imaging probes. In the following paragraphs the different
approaches to achieve speciﬁc retention of the imaging label will
be addressed. First, probes will be discussed that require the
presence of a speciﬁc target for activation and are not amend-
able to the detection of other targets. Thereafter, activatable
Figure 10. Mechanism of proteolytic actuation of iron oxide self-assem-
bly. Avidin- and biotin functionalized iron oxide nanoparticles are
shielded by PEG chains. Upon proteolytic removal of PEG, biotin and
neutravidin particles self-assemble into clusters, resulting in an enhanced
transverse relaxivity.
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molecular imaging probes will be discussed where retention can
be modulated by a wider variety of targets by including different
substrates/triggers.
5.1. Bioresponsive accumulating probes lacking tuning
possibilities for novel targets
In this section, activatable imaging probes will be discussed that
show retention and accumulation of the imaging label upon
activation. All these probes are designed to be speciﬁcally acti-
vated by a unique biomarker (e.g. speciﬁc enzyme, pH, hypoxic
tissue) and typically lack the possibility to be adapted to a wide
variety of targets.
5.1.1. Bioresponsive accumulating probes restricted to speciﬁc
enzymes
An example of an activatable imaging probe that has a narrow
target-application range has been developed by the group of
Ruoslahti (268,269). In their work, ﬂuorescent probes have been
developed that speciﬁcally penetrate integrin and neuropilin
overexpressing cells upon proteolytic activation. These probes
were successfully targeted to tumors through a three-step pro-
cess: ﬁrst an RGD-peptide motif mediated binding to integrins
on tumor endothelium. Subsequent proteolytic degradation of
the probe exposed a C-terminal R/KXXR/K motif, which mediated
neuropilin-1-dependent cellular penetration (269).
In another approach, ﬂuorescent, MRI, and radiolabeled probe
analogs were developed displaying speciﬁc cross-linking to
thrombi by the activity of transglutaminase FXIIIa (270–274). In
a mouse model of myocardial infarction, transglutaminase FXIIIa
activity was successfully detected using a radiolabeled analog
(273,274). Redesigning this probe to achieve cross-linking upon
interaction with other enzymatic targets, such as MMPs, that
do not show transglutaminase activity is cumbersome. Therefore
this type of imaging probe cannot be adapted to detect a wide
range of other targets. Recently, another MRI activatable probe
was developed that upon activation binds efﬁciently to ﬁbrin in
fresh thrombi (275). The probe is based on a low-afﬁnity ﬁbrin-
binding linear peptide that becomes cyclic by the activity of pro-
tein disulﬁde isomerase. Upon cyclization of the imaging probe,
the probe showed strongly enhanced ﬁbrin binding. Because
protein disulﬁde isomerase is only present on activated platelets
the activated MRI imaging probe predominantly bound to fresh
thrombi in vitro. Furthermore, a metalloporphyrin MRI imaging
probe was developed that became insoluble after cleavage of
phosphate end-groups by the reporter enzyme secreted alkaline
phosphatase (276). This probe showed strong accumulation and
T1 shortening in vivo in the vicinity of the areas expressing the
reporter enzyme.
Intracellular enzymatic targets have been successfully
targeted with radiolabeled probes showing increased retention
upon enzymatic activation. Intensive research over many de-
cades has resulted in various 18F activatable PET probes that
are intracellularly phosphorylated and subsequently trapped. A
well-known example is the clinically applied PET imaging probe
18F-ﬂuorodeoxyglucose (FDG) that is used for imaging of glucose
metabolism (277). Cancerous tissue typically has a high
metabolic activity characterized by an increased uptake of
glucose/FDG. Subsequently, the elevated intracellular activity
of the enzyme hexokinase enables efﬁcient phosphorylation of
FDG, resulting in cellular entrapment and subsequent accumula-
tion of the radiolabeled probe (Scheme 5) as further downstream
probe metabolism is blocked. Other phosphorylation sensitive
PET imaging probes have been developed for the imaging of cell
proliferation: 18F-ﬂuoro-3′-deoxy-3′-L-ﬂuorothymidine (FLT) and
Figure 11. (A) Mechanism of an uPA sensitive CEST agent (248). The horizontal reaction shows MR saturation of the amide proton (in red), followed by
CEST, which transfers the MR saturation to water and decreases the water signal. The vertical reaction shows cleavage of the ZGGR peptide by uPA,
which results in the conversion of the amide to an amine that does not generate CEST. (B) The uPA sensitive CEST probe showed CEST in the absence
of uPA but not after cleavage by uPA. Figure is reprinted (adapted) with permission from (248).
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18F-choline (278–280). FLT is a thymidine analog that is incorpo-
rated into the DNA of proliferative cells, such as those found in
tumor tissue. Once FLT is taken up by cells and phosphorylated
by thymidine kinase 1, it becomes trapped intracellularly (278).
18F-choline is incorporated in the membrane of cancer cells that
show increased lipid synthesis during tumor cell growth
(279,280). Speciﬁcally, choline is phosphorylated by choline
kinase and subsequently built into the cell membrane as phos-
phatidylcholine. Both FLT and 18F-choline are clinically used for
imaging of different types of proliferating cancers in patients
(280,281). Recently, an advanced H2O2 activatable FLT probe
was developed for ROS detection in proliferative cells (282). Vali-
dation of this probe in vivo is expected and such a probe may be
valuable for detection of ROS-producing cancers. Another paper
described a dual-strategy for imaging of secondary Cerenkov in-
duced ﬂuorescence using both FDG and an MMP-sensitive
ﬂuorescein-quencher optical probe (283). Local FDG nuclear radi-
ation will result in Cerenkov radiation, which can be absorbed by
the ﬂuorescein-containing optical probe. In case ﬂuorescein is
activated and released by MMP, absorption of Cerenkov radia-
tion will result in a ﬂuorescent signal. It was demonstrated that
this probe can detect concomitant enzyme and glycolytic activ-
ity in vivo (283). Another intracellular target that can phosphory-
late radiolabeled probes, leading to cellular probe accumulation,
is herpes simplex virus-1 thymidine kinase (284). In this ap-
proach, a probe, for example FIAU (1-(2’-deoxy-2’-ﬂuoro-1-β-D-
arabinofuranosyl)-5-iodouracil is used, which resembles the nu-
cleotide uridine. In contrast to mammalian thymidine kinase,
the herpex simplex virus-1 thymidine kinase (HSV1-TK) is less dis-
criminative and is able to phosphorylate these probes, leading to
trapping and accumulation in cells expressing HSV1-TK. This en-
zyme is extensively used in reporter gene imaging approaches
using PET or SPECT as a research tool (284,285), but has also clin-
ically been tested in glioma imaging (286) as well as in combina-
tion with ganciclovir in enzyme/prodrug therapy of gliomas
(287). Zhang et al. developed a FRET imaging probe for the de-
tection of Bruton’s tyrosine kinase in live cells (288). Reaction of
the imaging probe with kinase resulted in removal and cellular
washout of the quencher and activation and retention of the
optical imaging label.
Next to kinases, other intracellular enzymes such as caspases,
indicative for apoptosis, have been targeted with activatable im-
aging probes resulting in enhanced retention. For example,
radiolabeled cell-penetrating caspase substrates were developed
for SPECT imaging and showed enhanced retention in apoptotic
cells in vitro (289) and in tumors in vivo (290).
Finally, dynamic changes in glycosylation, the posttransla-
tional modiﬁcation of proteins, are associated with tumor
progression (291). Therefore, imaging strategies have been ex-
plored to image tissue glycosylation in vivo (292,293). In these
strategies, bioresponsive sugar analogues containing a bio-
orthogonal functional group (e.g. azide) are metabolized and
incorporated into cell-surface glycans. The azide can subse-
quently react with imaging probes bearing a complementary
bioorthogonal functional group. This technique was demon-
strated in zebraﬁsh (294), but translation to rodents to speciﬁ-
cally visualize tumor tissue has proven challenging, as the
azidosugars are metabolized and incorporated into glycans in
various tissues (291). Therefore, Xie et al. employed targeted lipo-
somes to deliver the bioresponsive azidosugars speciﬁcally to
the tumor tissue. Tumor glycan-speciﬁc incorporation of the
azidosugars in vivo was demonstrated using a bioorthogonal op-
tical imaging probe (291).
5.1.2. Bioresponsive probes accumulating in acidic tissues
Differences in pH between diseased and healthy tissue have
been used to mediate the retention of imaging probes in
diseased tissues. For example, an electrostatically quenched
cell-penetrating micelle was selectively activated at the lower
extracellular pH of the tumor microenvironment (on average
pH is between 6 and 7 (130)), resulting in intracellular
accumulation and release of a model drug (295). This model
system may also be used to release and activate optical imaging
probes (Fig. 12). An alternative approach is aimed at the local
Scheme 5. Phosphorylation of FDG.
Figure 12. Mechanism of a pH-dependent cell-penetrating micelle. The
cell-penetrating property of polycationic peptide functionalized micelles
is masked by polyanionic polymers. At pH < 7.0 dissociation will take
place, leading to cellular uptake of the micelle. Subsequent leakage of
the ﬂuorophores will result in restoration of ﬂuorescence.
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release and accumulation of iron-oxide particles from
pH-responsive polymeric micelles at acidic conditions (296). This
activatable T2 MRI contrast agent was used for the detection of
ischemic areas in the brain of rats. Furthermore, pH-dependent
cell-membrane insertion peptides containing either a ﬂuorescent
or a radioactive imaging label were developed and showed efﬁ-
cient membrane tagging and speciﬁc retention in acidic tumor
tissues (297,298).
5.1.3. Bioresponsive probes accumulating in hypoxic tissues
Over the past decades, much research has been devoted to the
development of imaging probes for detection of hypoxic areas,
often encountered in tumors that grow beyond the region
reached by vascular oxygen (299,300). The ﬁrst probes were
based on radiolabeled 2-nitroimidazoles. After cellular entry via
diffusion, the 2-nitroimidazole moiety undergoes an enzyme-
mediated single-electron reduction to produce reactive oxygen
radical anions. In normoxic tissues, the radical anion is rapidly
back-oxidized to the original compound and eventually diffuses
out of the cells and tissues. In hypoxic tissues, however, the rad-
ical anion may be further reduced and subsequently will be
trapped in cells via covalent binding to the macromolecular
components (301). A PET imaging probe, 18F-ﬂuoromisonidazole
(FMISO), has been administered in patients and demonstrated to
be a valuable tool for the evaluation of tumor response during
and after fractionated radiation therapy (302). Second- and
third-generation 2-nitroimidazole probes (18F-ﬂuoroazomycin
arabinoside (FAZA) and 18F-ﬂortanidazole (HX4)) have also
shown promising in vivo results in patients with head and neck
cancer (303–305). Another well-studied probe is 64Cu-diacetyl-
bis(N4-methylthiosemicarbazonate), Cu-ATSM. Upon cellular up-
take, Cu(II)-ATSM is reduced to an unstable Cu(I)-ATSM probe,
followed by dissociation of the metal complex and subsequent
irreversible trapping of Cu(I) within the cell (306). While other
processes such as copper metabolism may play a role in
Cu-ATSM tumor uptake, this probe showed clinical value
for patient diagnostics (299,306,307). Furthermore, other
hypoxic imaging probes have recently been developed. A
4-nitrobenzylester-containing 99mTc-probe showed efﬁcient
reduction to a cell-membrane impermeable carboxylate anion
with consequent cellular retention in vitro (308). Finally, a
radiolabeled-peptide-based probe was developed that was de-
graded and retained in hypoxia-inducible factor-1 active tumor
regions in vivo (309).
5.2. Bioresponsive accumulating probes enabling tuning
for target speciﬁcity
In this section, bioresponsive accumulating molecular imaging
probes will be discussed that can be applied for the detection
of a wide variety of targets. A ﬁrst class of probes exhibit hydro-
phobic clustering upon proteolytic removal of a hydrophilic
component, thereby decreasing the in vivo clearance rate from
the target tissue (310–312) (Fig. 13). These probes showed good
promise for the detection of MMP-2 and MMP-7 in vivo,
employing MRI T1-contrast agents as imaging labels (310–312).
Recently, this concept was further developed for PET purposes.
Hereto, an 18F-labeled hydrophobic tetramethylrhodamine moi-
ety was conjugated to a hydrophilic PEG linker by an MMP-2
cleavable substrate (313).
A second imaging concept was proposed by Tsien and co-
workers. They reported on activatable cell-penetrating peptide
(ACPP) imaging probes functionalized with ﬂuorophores or MRI
contrast agents (314–319) (Fig. 14A). These constructs consisted
of an MMP-2/9 substrate inserted in between a polyanionic pep-
tide and a polycationic cell-penetrating peptide (CPP) conju-
gated to the imaging probe. The cell-penetrating property of
the polycationic peptide was neutralized due to intramolecular
electrostatic interactions with the polyanionic domain,
preventing cellular uptake of the probe. Cleavage of the sub-
strate by tumoral MMP-2/9 released the polycationic from the
polyanionic domain, thereby triggering cellular adhesion and
subsequent uptake of the imaging label-functionalized
polycationic peptide in tumors. A threefold higher tumor uptake
was observed for MMP-2/9 ACPP compared to a scrambled neg-
ative control (314). However, it was recently demonstrated that
the tumor targeting of a radiolabeled MMP-2/9 sensitive ACPP
Figure 13. (A) Chemical structure of a MMP-2 activatable solubility switchable MRI T1-contrast agent (310). A Gd
3+-DOTA functionalized hydrophobic
alkyl chain is conjugated to a hydrophilic PEG chain via an MMP-2 cleavable peptide substrate (RSPAY-YTAA). (B) Schematic representation; upon pro-
teolytic removal of the hydrophilic PEG chain, the alkyl chain will provide a decrease in solubility, resulting in tissue retention of the Gd-labeled domain
at the target site and subsequent enhanced T1-relaxivity.
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is most likely not caused by tumor-speciﬁc activation but due to
activation of ACPP in the vasculature and subsequent elevated
uptake in the tumor due to its enhanced permeability
(320,321). In this work, dual-isotope radiolabeled ACPPs have
been designed that allow in vivo discrimination between uptake
of the activated probe and the integral probe (Fig. 14B). Most
likely, tumor-speciﬁc ACPP activation have been limited due to
low absolute tumoral MMP activity as a result of local MMP inhi-
bition by the family of tissue inhibitors of metalloproteinases
(TIMPs) (321,322). In a cardiovascular-disease-related mouse
model, a dual-isotope radiolabeled MMP-2/9 sensitive ACPP
probe was successfully employed to detect MMP activity in the
context of post-ischemic myocardial remodeling (323) (Fig. 14C
and D). Furthermore, a ratiometric Cy5/Cy7 labeled MMP-2/9
sensitive ACPP probe allowed the real-time detection of MMP
activity in a murine asthma model (324).
The ACPP imaging concept was further explored for the detec-
tion of disease-related enzymes such as urokinase, enterokinase,
MMP-14, and plasmin in vitro (314,325–327), as well as acidic
conditions, by employing a reduction-sensitive disulﬁde bridge
between the polycationic and polyanionic domain (314). A novel
tumor-homing ACPP, predominantly sensitive for elastases, was
identiﬁed by a parallel in vitro and in vivo selection with phage
displaying a library of ACPPs (328). Introduction of a NIR
quencher at the polyanionic domain led to development of
MMP-2 and MMP-7 FRET-based ACPP imaging probes that
showed both in vitro activation of ﬂuorescence as well as cellular
retention upon cleavage (202,329). Furthermore, the similar
MMP-2 ACPP probe was succesfully employed in photoacoustic
imaging of MMPs in thyroid carcinomas in vivo (203). Recently,
progress was made in the development and application of
ratiometric ACPP imaging probes for in vivo detection of throm-
bin (330,331) and H2O2 (167). Finally, it was shown that cellular
uptake of ACPP functionalized nanocarriers in vitro, that is, MRI
contrast agent functionalized dendrimers (317) or quantum dots
(332), could be modulated by MMP-2. MMP-induced cellular up-
take of quantum dots in vitro was also achieved by dePEGylation
of CPP functionalized quantum dots (333).
Recently, a new class of activatable oligomerizable imaging
probes has been developed. These probes contain both a
N-terminal cysteine residue and a 6-amino-CBT group, in which
the former group is protected by a protease-sensitive sub-
strate. Removal of the substrate will liberate the N-terminal
D-cysteine residue, allowing an intermolecular condensation
reaction between D-cysteine and 6-amino-CBT, yielding a linear
oligomer that accumulates. This strategy has been successfully
employed to detect intracellular furin by optical and photo-
acoustic imaging (334,335) and might be applicable to other
intracellular proteases that yield an N-terminal cysteine upon
cleavage.
In another approach, cell-internalization was achieved upon
activation of a lipid-containing FRET probe (336). This probe
was targeted to the plasma membrane and activation of the
probe by MMP-12 resulted in efﬁcient internalization and reten-
tion of the donor ﬂuorophore.
Finally, bioresponsive accumulating probes have been devel-
oped that need a second target for site-speciﬁc retention after
its initial activitation. For example, protease-activatable probes
have been designed to result in speciﬁc retention of the imaging
label by tagging of an MMP-2/14 activated transmembrane do-
main to the cell membrane (337) or speciﬁc internalization of
an MMP-9 activated probe into scavenger receptor class A type
Figure 14. (A) Mechanism of a ﬂuorescently labeled protease
activatable cell-penetrating peptide (ACPP). The cell-penetrating prop-
erty of a polycationic peptide is masked by a polyanionic peptide. Pro-
teolytic degradation of the linker releases the polycationic cell-
penetrating peptide, which will transfer the ﬂuorophore label across
the cell membrane. (B) Mechanism of a dual-isotope radiolabeled prote-
ase activatable cell-penetrating peptide. Proteolytic degradation of the
linker releases the polycationic cell-penetrating peptide, which will trans-
fer its radionuclide cargo (in blue) across the cell membrane. The
polyanionic peptide and its radionuclide cargo (in red) will be cleared
from the target tissue. The ratio of the radionuclide cargoes (blue-over-
red) is a measure for local ACPP activation. (C) Imaging of MMP-activity
in post-ischemic cardiac remodeling using an MMP-2/9 sensitive
radiolabeled ACPP. (D) Azan staining of an adjacent coronal section
showing the infarct scar in blue and remote myocardium in red. Figure
C and D are reprinted with permission from van Duijnhoven et al. (323).
Copyright 2014 American Chemical Society.
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I expressing macrophages (338). Another example is a ﬂuores-
cent probe that showed enhanced binding to collagen ﬁbers
upon proteolytic activation in vitro (339,340).
6. CONCLUDING REMARKS
In summary, this review highlights the state-of-the-art of the
design and potential application of bioresponsive molecular
imaging probes for the monitoring of endogenous targets
in vivo. Various strategies of bioresponsive imaging probes have
been discussed, varying from protease activatable probes for
which the molecular target can continuously activate the imag-
ing probe to a broad spectrum of other endogenous targets
for which the imaging label either undergoes a transition from
an “off” to an “on” state or is speciﬁcally retained at the site of
activation. Current and novel bioresponsive molecular imaging
probes may play a pivotal role in gathering molecular infor-
mation underlying biological and cellular processes in basic
biology and disease. Therefore, we strongly believe that
bioresponsive probes will ﬁnd various clinical applications,
including in (i) diagnostics to improve accurate detection of
disease, (ii) intraoperative imaging-guided surgery to improve
tumor margin detection, and (iii) real-time assessment of efﬁcacy
of therapy/surgery.
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